September 22, 2022
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 15, 2022
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
September 6, 2022
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
August 9, 2022
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
June 16, 2022
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
May 18, 2022
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
May 12, 2022
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
April 7, 2022
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
March 1, 2022
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
Displaying 1 - 10 of 14